Tao Yu-Hong, Ye Li, Wang Ya-Mei, Wang Zheng
Department of Pediatrics, Sichuan University, Chengdu, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2013 Feb;15(2):157-61.
Preclinical studies have demonstrated that exogenous mesenchymal stem cells (MSCs) may ameliorate kidney damage and enhance repair of renal ischemia reperfusion injury (IRI). This review will focus on the mechanism for accelerating repair of renal IRI by MSCs. Several chemokine receptors such as CXCR4 and CD44 are related to MSCs trafficking to post-ischemic kidney. MSCs differentiate into tubular epithelial cells, which is not the predominant mechanism for repair of the damaged kidney. Instead, MSCs exert their therapeutic effect mainly through paracrine action via a variety of cytokines and microvesicles, and the paracrine actions of infused MSCs work to activate intrinsic kidney cells, promote angiogenesis, inhibit oxidative stress and reduce apoptosis, inflammation and renal fibrosis.
临床前研究表明，外源性间充质干细胞（MSCs）可能改善肾脏损伤并增强肾缺血再灌注损伤（IRI）的修复。本综述将聚焦于MSCs加速肾IRI修复的机制。几种趋化因子受体，如CXCR4和CD44，与MSCs向缺血后肾脏的归巢有关。MSCs分化为肾小管上皮细胞，这并非受损肾脏修复的主要机制。相反，MSCs主要通过多种细胞因子和微泡的旁分泌作用发挥其治疗效果，注入的MSCs的旁分泌作用可激活肾脏固有细胞、促进血管生成、抑制氧化应激并减少细胞凋亡、炎症和肾纤维化。
